BiolineRx

Company Overview

Snapshot

Founded in April 2003, BiolineRx operates with 51–200 employees and has raised a total of $208.64 million across 18 funding rounds from 10 investors. In September 2023, the company announced FDA approval of APHEXDA™ (motixafortide) for multiple myeloma patients.

Business overview

BiolineRx is a clinical-stage biopharmaceutical company specializing in oncology. The company's pipeline includes BL-8040, a platform for various cancer and hematological indications, and AGI-134, a synthetic immunotherapy for solid tumors. BiolineRx focuses on identifying, validating, and in-licensing therapeutic candidates that offer advantages over existing treatments or address unmet medical needs. The company also collaborates with partners like Novartis and MSD (Merck in the US and Canada) on drug development and clinical trials, operating within the Health Tech & Life Sciences sector.

Strategic signal

In September 2025, BioLineRx Ltd. and Hemispherian AS established a joint venture to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers. This collaboration signals BioLineRx's strategic expansion into novel therapeutic areas and advanced cancer treatments, indicating a focus on pipeline diversification and addressing high-unmet medical needs in oncology.

Company Intelligence Q&A

What was a significant regulatory milestone for BioLineRx in late 2023?

In September 2023, BioLineRx announced the FDA approval of APHEXDA™ (motixafortide) in combination with Filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.

What strategic partnership did BioLineRx form in September 2025?

In September 2025, BioLineRx Ltd. and Hemispherian AS established a joint venture to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers.

What was the outcome of the Phase 2 combination clinical trial for Motixafortide in pancreatic cancer in September 2023?

In September 2023, BioLineRx announced encouraging data from the pilot phase of its Phase 2 combination clinical trial with Motixafortide in first-line pancreatic cancer (PDAC).

What licensing agreement did BioLineRx close in October 2023?

In October 2023, BioLineRx announced the closing of an exclusive license agreement for Motixafortide in Asia, which included a concurrent strategic equity investment.

What patent allowance did BioLineRx receive in October 2024?

In October 2024, BioLineRx announced that the USPTO allowed a new composition of matter patent on Motixafortide.